Skip to main navigation Skip to search Skip to main content

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)

  • Thoracic Oncology Research Group (TORG)

Research output: Contribution to journal › Article › peer-review

13   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases